Stent with protruding branch portion for bifurcated vessels

Abstract
The present invention is directed to a stent for use in a bifurcated body lumen having a main branch and a side branch. The stent comprises a radially expandable generally tubular stent body having proximal and distal opposing ends with a body wall having a surface extending therebetween. The stent also comprises a branch portion that is deployable outwardly from the stent body into a branch vessel.
Description
FIELD OF THE INVENTION

The present invention relates to the field of medical stents and, more particularly, to a stent for the treatment of lesions and other problems in or near a vessel bifurcation.


BACKGROUND OF THE INVENTION

A stent is an endoprosthesis scaffold or other device that typically is intraluminally placed or implanted within a vein, artery, or other tubular body organ for treating an occlusion, stenosis, aneurysm, collapse, dissection, or weakened, diseased, or abnormally dilated vessel or vessel wall, by expanding the vessel or by reinforcing the vessel wall. In particular, stents are quite commonly implanted into the coronary, cardiac, pulmonary, neurovascular, peripheral vascular, renal, gastrointestinal and reproductive systems, and have been successfully implanted in the urinary tract, the bile duct, the esophagus, the tracheo-bronchial tree and the brain, to reinforce these body organs. Two important current widespread applications for stents are for improving angioplasty results by preventing elastic recoil and remodeling of the vessel wall and for treating dissections in blood vessel walls caused by balloon angioplasty of coronary arteries, as well as peripheral arteries, by pressing together the intimal flaps in the lumen at the site of the dissection. Conventional stents have been used for treating more complex vascular problems, such as lesions at or near bifurcation points in the vascular system, where a secondary artery branches out of a larger, main artery, with limited success rates.


Conventional stent technology is relatively well developed. Conventional stent designs typically feature a straight tubular, single type cellular structure, configuration, or pattern that is repetitive through translation along the longitudinal axis. In many stent designs, the repeating structure, configuration, or pattern has strut and connecting members that impede blood flow at bifurcations. Furthermore, the configuration of struts and connecting members may obstruct the use of post-operative devices to treat a branch vessel in the region of a vessel bifurcation. For example, deployment of a first stent in the main lumen may prevent a physician from inserting a branch stent through the ostium of a branch vessel of a vessel bifurcation in cases where treatment of the main vessel is suboptimal because of displaced diseased tissue (for example, due to plaque shifting or “snow plowing”), occlusion, vessel spasm, dissection with or without intimal flaps, thrombosis, embolism, and/or other vascular diseases. As a result, the physician may choose either to insert a stent into the branch in cases in which such additional treatment may otherwise be unnecessary, or alternatively the physician may elect not to treat, or to “sacrifice”, such side lumen. Accordingly, the use of regular stents to treat diseased vessels at or near a vessel bifurcation may create a risk of compromising the benefit of stent usage to the patient after the initial procedure and in future procedures on the main vessel, branch vessels, and/or the bifurcation point.


A regular stent is designed in view of conflicting considerations of coverage versus access. For example, to promote coverage, the cell structure size of the stent may be minimized for optimally supporting a vessel wall, thereby preventing or reducing tissue prolapse. To promote access, the cell size may be maximized for providing accessibility of blood flow and of a potentially future implanted branch stent to branch vessels, thereby preventing “stent jailing”, and minimizing the amount of implanted material. Regular stent design has typically compromised one consideration for the other in an attempt to address both. Problems the present inventors observed involving side branch jailing, fear of plaque shifting, total occlusion, and difficulty of the procedure are continuing to drive the present inventors' into the development of novel, non-conventional or special stents, which are easier, safer, and more reliable to use for treating the above-indicated variety of vascular disorders.


Although conventional stents are routinely used in clinical procedures, clinical data shows that these stents are not capable of completely preventing in-stent restenosis (ISR) or restenosis caused by intimal hyperplasia. In-stent restenosis is the reoccurrence of the narrowing or blockage of an artery in the area covered by the stent following stent implantation. Patients treated with coronary stents can suffer from in-stent restenosis.


Many pharmacological attempts have been made to reduce the amount of restenosis caused by intimal hyperplasia. Many of these attempts have dealt with the systemic delivery of drugs via oral or intravascular introduction. However, success with the systemic approach has been limited.


Systemic delivery of drugs is inherently limited since it is difficult to achieve constant drug delivery to the inflicted region and since systemically administered drugs often cycle through concentration peaks and valleys, resulting in time periods of toxicity and ineffectiveness. Therefore, to be effective, anti-restenosis drugs should be delivered in a localized manner.


Although prior art references disclose numerous stents configurations, some of which are coated with one or more drugs, there still remains a need for a stent design that can effectively provide ostial branch support in a vessel bifurcation and effectively act as a delivery vehicle for drugs. Further, there is a need for a bioabsorbable bifurcated stent. This is particularly true in complicated cases, such as lesions located at a bifurcation.


SUMMARY OF THE INVENTION

The present invention is directed to a stent for use in a bifurcated body lumen having a main branch and a side branch. The stent comprises a radially expandable generally tubular stent body having proximal and distal opposing ends with a body wall having a surface extending therebetween. The surface has a geometrical configuration defining a first pattern, and the first pattern has first pattern struts and connectors arranged in a predetermined configuration. The stent also comprises a branch portion comprised of a second pattern, wherein the branch portion is at least partially detachable from the stent body.


In one embodiment of the invention, a bifurcation stent is provided, which comprises a tubular member having an inner diameter and an outer diameter defining a wall therebetween, the wall having a geometrical configuration defining a pattern; and an expandable branch structure formed in the wall of the tubular structure and interrupting the wall pattern, the expandable branch structure having a first ring connected to the tubular member, a second ring connected to the first ring and a third ring connected to the second ring, wherein the expandable branch structure includes a distal portion and a proximal portion, and at least one partial distal ring is connected to the first ring at the distal portion and at least one partial distal ring is connected to the first ring at the proximal portion, and wherein the rings and the partial rings at the proximal and distal portions form a lattice portion, wherein the third ring substantially surrounds and defines a central branch opening, and wherein the expandable branch structure is movable from an unexpanded configuration to an expanded configuration, in the unexpanded configuration the expandable branch structure is disposed along the wall and in the expanded configuration the expandable branch structure extends outwardly from the tubular member.


In another embodiment, the stent's tubular member has a longitudinal axis and the expandable branch structure is disposed substantially perpendicular to the longitudinal axis in the expanded configuration. In a further embodiment, the stent's tubular member comprises a plurality of undulating rings disposed along the longitudinal axis and the undulating rings are connected by connectors. In another embodiment, the first, second and third rings have a common axis disposed substantially perpendicular to the longitudinal axis in the unexpanded configuration.


In a further embodiment of the invention, the branch structure of the stent includes a transition structure. In another embodiment, the transition structure comprises a discontinuous portion. In a further embodiment of the invention, the first ring connects to the discontinuous portion, connects the first ring to a portion of the wall pattern outside the extendible branch structure.


In another embodiment, the first, second and third rings are connected by connectors. In other embodiments, the connectors are generally undulating curvilinear members. In still further embodiments, the connectors are generally straight members. In a further embodiment of the invention, the first, second and third rings are generally continuous undulating curvilinear members and include undulation peaks.


In other embodiments, the stent is comprised of biodegradable material. In further embodiments, the stent is comprised of a material and is coated with a biodegradable material. In further embodiments of the invention, the stent is one of comprised of or coated with a biodegradable material including a drug embedded in the material, whereby upon degradation of the biodegradable material, the drug is controllably released. In another embodiment, the biodegradable material is at least one of polyglycolic acid, polylactic acid, copolymers of polyglycolic acid and polylactic acid, polyorthoesters, polyaminoacids and polyanhydides. In another embodiment, the drug can be embedded in the material in one amount on the expandable branch structure and in another amount on a remainder of the tubular member. In a further embodiment, the first, second and third rings are concentric.


In another embodiment, the first ring is connected to a tubular member by a connector having at least one cell. In one embodiment, the second pattern is configured according to the first pattern having at least one absent connector, and in another embodiment, the second pattern has a plurality of absent connectors. The second pattern may have second pattern struts, and the second pattern struts can be more densely packed than the first pattern struts.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented to provide what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the invention may be embodied in practice.


In the drawings:



FIG. 1 is an illustration of a blood vessel bifurcation and an unexpanded stent mounted on an exemplary stent delivery system.



FIG. 2 is an illustration of the stent of FIG. 1 in an expanded condition.



FIG. 3 is a flat view of an embodiment of an unexpanded stent in accordance with the present invention.



FIG. 4 is an end view of the stent in FIG. 3 in the expanded condition.



FIG. 5 is a flat view of another embodiment of an unexpanded stent in accordance with the present invention.



FIG. 6 is a flat view of another embodiment of an unexpanded stent in accordance with the present invention.



FIGS. 7-9 are illustrations of the steps for a method of inserting a stent of the present invention according to one embodiment of the invention.





DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is directed to a bifurcated stent of the type described in co-pending application Ser. No. 10/802,036, filed Mar. 17, 2004, the disclosure of which is incorporated by reference. In particular, the present invention relates to stents for placement at vessel bifurcations and that are generally configured to cover a portion of a branch vessel as well as a main vessel. Referring to FIGS. 1 and 2, an exemplary bifurcated blood vessel and bifurcated stent, in accordance with the principles of the invention, are shown. The vessel has a main vessel 2 and a branch vessel 4. Main vessel 2 and branch vessel 4 are disposed at an angle 11, which can be any angle but is shown as an angle of less than 90 degrees by way of example. With reference to FIG. 1, bifurcated stent 10 is shown in an unexpanded condition in FIG. 1. FIG. 2 shows stent 12 in an expanded configuration where branch portion 30 is outwardly deployed from the stent main portion as shown in a representative expanded state in the vasculature.


Stent 12 according to one embodiment of the present invention comprises stent body or wall 14 extending along a longitudinal axis 3 from a proximal end 20 to a distal end 22 and defining a lumen therein. Stent 12 may have a three-dimensional geometrical configuration having variable dimensions (length, width, height, depth, thickness, etc.). In a preferred embodiment, stent body 14 is a generally tubular structure. As defined herein, “tubular” can include an elongate structure that has varied cross-sections and does not require that the cross-section be circular. For example, the cross-section of stent wall 14 may be generally oval. In an alternate embodiment, stent body 14 is generally cylindrical. Also, the stent body 14 may have varied cross-sectional shapes along the longitudinal axis 3 of the stent. For example, the circumferences in the proximal and distal parts of the stent may be different. This may occur, for example, if during stent delivery the delivery system causes the stent to distend. A lumen represents the inner volumetric space bounded by stent body. In a preferred embodiment, stent 12 is radially expandable from an unexpanded state to an expanded state to allow the stent to expand radially and support the main vessel. In the unexpanded state, the stent body defines a lumen having a first volume, and in the expanded state, as illustrated in FIG. 1, the stent body defines a lumen having a second volume larger than the first volume.



FIG. 3 shows stent 112 in an unexpanded state in a flattened elevational view. Stent body 114 has a generally cellular configuration and comprises a generally repeatable series of struts and connectors configured in a predetermined general, overall, or main pattern at the proximal 122 and distal 120 ends of stent 12. Many other strut and connector patterns may be used, and the present pattern is shown for illustration purposes only.


Stent 112 further includes a branch portion 130 located at some point along the length of stent 112. Branch portion 130 comprises a section or portion of stent wall 114 that is configured to extend into a branch vessel in a vessel bifurcation as discussed above. In general, branch portion 130 is configured to be movable from an unextended position to an extended position. In the unextended position, branch portion 130 is disposed in the volume defined by the unexpanded stent 112, that is, the branch portion 130 does not protrude radially from stent wall 114 as illustrated in FIG. 1. In the extended position, the branch portion 130 extends outwardly from stent wall 114 and branch portion 130 is extended into the branch vessel as illustrated in FIGS. 2 and 4. Branch portion 130 comprises a stent wall section of stent body 114 that is initially flush, coplanar, or cocylindrical with the remainder of stent body 114 and may extend outwardly with respect to the remainder of stent body 114. This configuration allows for access into a branch vessel, and at the same time allows for circumferential alignment of the stent within the vessel prior to deployment. In other embodiments, multiple branch portions can be incorporated into the stent to permit multiple access to one or more vessels. In a preferred embodiment, branch portion 130 may be positioned in the midsection of stent 112. In alternate embodiments, branch portion 130 may be positioned anywhere along the length of stent 112.


The details of branch portion 130 will be discussed. Branch portion 130 includes three interconnected rings 141, 142 and 143. As shown, rings 141, 142 and 143 are concentric, but could be non-concentric. The inner ring 141 defines undulation petals, prongs, or peaks surrounding a central branch opening 108. Branch opening 108 provides access to the side branch vessel when stent 112 is in the unexpanded condition. In this embodiment, undulation peaks of inner ring 141 are configured differently from the other rings. Rings 142 and 143 are formed, generally, from undulating configurations as shown. The amount and particular configuration of the rings is provided to allow for expansion into the branch. When stent 112 is expanded, as shown in FIG. 4, branch portion 130 is extended into the branch vessel (not shown), causing the expandable rings 141, 142 and 143 to at least partially cover the inner surface of the branch vessel. Thus, in a preferred embodiment, the stent coverage in a portion of the branch vessel includes the full circumference of the inner branch vessel wall. Branch portion 130 may include an auxiliary access opening to provide access to the side branch vessel as described in co-pending application Ser. No. 10/802,036 filed Mar. 17, 2004. Also, in the branch portion 130 may be modified to accommodate markers. Rings 141, 142 and 143 can be interconnected by a plurality of inner connectors as shown.


Outer ring 143 is connected to elliptical transition members 148 as shown and outer connectors 154, which can be generally S-shaped, zigzag-shaped, or wavelike. In this regard, the wavelike shape of distal outer connectors may be deformed to a greater extent and accommodate more expansion than, for example, a straight outer connector design. Outer ring 143 can be connected to partial rings 144 and 145 at the proximal and distal ends of stent 112. Partial ring 144 as shown has four undulations and ring 145 has one. These additional partial rings provide for a lattice configuration at the proximal and distal portion of the branch structure improving coverage thereat. Thus, with this configuration, more coverage is provided when the stent is expanded. Also, with this configuration, varying degrees of coverage or radial support of the side branch vessel wall upon installation into a side branch vessel can be provided. In alternate embodiments, other geometries may be used.


The branch portion 130 protrudes into the branch vessel when the stent is fully expanded. FIG. 4 shows an end view of stent 112 in an expanded configuration. The branch portion upon expansion can extend into the branch vessel in different lengths depending upon the application. The amount of extension may vary in a range between about 0.1-10.0 mm. In one preferred embodiment, the length of extension is 1-3 mm. In another preferred embodiment, the length of extension is approximately 2 mm. In alternative embodiments, the amount of extension into the branch vessel may be variable for different circumferential segments of branch portion 130. As shown in each of the embodiments, the branch portion is approximately 2.5 mm in width and about 2.5-3.0 mm in length. However, the branch portion can be dimensioned to accommodate varying size branch vessels. The branch portion can be formed of any tubular shape to accommodate the branch vessel, including, oval or circular, for example.



FIG. 5 shows an alternate embodiment of the stent shown in FIG. 3. In the embodiment of FIG. 5, stent 212 has substantially the same construction except that additional connectors 160 are provided. Connectors 160 provide additional coverage in the branch vessel.



FIG. 6 shows an alternate embodiment of the stent shown in FIG. 3. In the embodiment of FIG. 6, stent 312 has substantially the same construction except that connectors 354 are different. Connectors 354 comprise a cellular structure each including three cells 370, 372 and 374. This cellular structure provides improved coverage and radial support. Additionally ring 342 includes a different pattern. Ring 342 has undulations with certain peaks modified to improve coverage.


In general, a wide variety of delivery systems and deployment methods may be used with the aforementioned stent embodiments. For example, a catheter system may be used for insertion and the stent may be balloon expandable or self-expandable, or the stent may be balloon expandable and the branch portion self-expandable, or vice versa. Once the stent is in position in the main vessel and the branch portion is aligned with the side branch the stent can be expanded. If the stent is balloon expandable, the stent may be expanded with a single expansion or multiple expansions. In particular, the stent can be deployed on a stent delivery system having a balloon catheter and side sheath as described, for example, in U.S. Pat. Nos. 6,325,826 and 6,210,429, the entire contents of which are incorporated herein by reference. In one preferred embodiment, a kissing balloon technique may be used, whereby one balloon is configured to expand the stent and the other balloon is configured to extend the branch portion. After the main portion of the stent is expanded in the main vessel, the stent delivery system may be removed and a second balloon may be passed through the side hole in the branch portion and expanded to expand the branch portion of the stent. In an alternate embodiment, the same balloon may be inserted in the main vessel inflated, deflated, retracted and inserted into the branch vessel, and then reinflated to expand the branch portion and cause it to protrude into the branch vessel. Alternatively, the stent can be delivered on two balloons and the main portion and the branch portion can be expanded simultaneously. As needed, the branch portion can be further expanded with another balloon or balloons. Yet another alternative is to use a specially shaped balloon that is capable of expanding the main and branch portions simultaneously. The stent can also be deployed with other types of stent delivery systems. Alternatively, the stent, or portions of the stent, can be made of a self-expanding material, and expansion may be accomplished by using self-expanding materials for the stent or at least the branch portion thereof, such as Nitinol, or by using other memory alloys as are well known in the prior art.


The construction and operation of catheters suitable for the purpose of the present invention are further described in U.S. patent application Ser. No. 09/663,111, filed Sep. 15, 2000, U.S. patent application Ser. No. 10/834,066, filed Apr. 29, 2004, and U.S. patent application Ser. No. 10/893,278, filed Jul. 19, 2004, the disclosures of which are incorporated herein by reference. It should be noted that the catheters taught in the above applications are exemplary, and that other catheters that are suitable with the stents of the subject application are included within the scope of the present application. In alternative embodiments, catheters without balloons may be used. For example, if the stent is comprised of memory alloy such as Nitinol, or is a mechanically self-expanding stent, balloons are not necessarily included on the catheters. Furthermore, any other catheter, including ones that are not disclosed herein, may be used to position stents according to the present invention.


Referring now to FIGS. 7-9, illustrations of the steps of a method for employing a stent of the present invention is shown. By way of example, the method is depicted utilizing stent 112. The depicted method may be accomplished using a catheter system having a main catheter 631 including a herniated balloon 635 (FIG. 9). In particular, the stent can be deployed on a stent delivery system having a herniated balloon as described, for example, in U.S. patent application Ser. No. 10/834,066, the entire contents of which are incorporated herein by reference. As shown in FIG. 7, the catheter 631 includes a balloon 635 that has a protruding portion 637 that, upon expansion, protrudes outwardly from the cylindrical outer surface of the balloon causing the branch portion 130 to be extended into branch vessel 4.


Referring again to FIGS. 7-9, protruding portion 637 may be configured to fit directly into an opening in the stent. As shown in FIG. 7, catheter 631 is advanced over a guidewire 633 and positioned proximal to the bifurcation. As shown in FIG. 8, the catheter is advanced until the protruding portion 637 of the balloon is positioned at the bifurcation. In one embodiment, protruding portion 637 protrudes outwardly from catheter 631 enough so that it actually comes into contact with the bifurcation, thus providing a method of alignment with the branch vessel 4. Finally, as shown in FIG. 9, balloon 635 is expanded, which simultaneously causes the stent to expand and branch portion 130 to be pushed toward the branch vessel 4. Upon inflation of the balloon, the herniated portion 637 expands and extends through the branch portion 130 toward the side branch to open the entrance of the occluded side branch artery.


In an alternative method, the stent can be delivered using a herniated balloon and a dual lumen delivery system. This system can include a main catheter defining a first lumen with concentric guidewire lumen and balloon inflation lumen, a herniated balloon, as described above, on the main catheter, a side sheath with a guidewire lumen, and a stent. The stent is crimped over the main catheter, balloon and side sheath with the side sheath exiting the stent through a branch opening or side hole. The distal end of the side sheath is used for aligning the stent branch opening with the branch vessel 4.


The appendage or herniation may be located on a second catheter or side sheath of the delivery system, such as the system or as a bifurcated or split herniated balloon as described in U.S. patent application Ser. No. 10/834,066, and U.S. patent application Ser. No. 10/893,278, which are incorporated herein by reference.


One particular application for the use of a stent with a branch portion such as the one described above is for localized drug delivery. Restenosis, including in-stent restenosis, is a common problem associated with medical procedures involving the vasculature. Pharmaceutical agents have been found to be helpful in treating and/or preventing restenosis, and these are best delivered locally to the site of potential or actual restenosis, rather than systemically. Stents according to the present invention can also be used as vehicles for localized delivery of other drugs.


The stent in accordance with the invention can be made of any material or combination of materials including stainless steel and/or biodegradable materials. For example, the stent can be made of solely biodegradable material or a conventional material coated with biodegradable material. A drug, drug compound or pharmaceutical agent can be used, for example, by embedding it in the biodegradable material. This can accomplish, among other things, time release. In particular, upon degradation of the stent or coating, the drug is released in a controllable preprogrammed fashion. Biodegradable polymers that are usable in the context of the present invention include, without limitation, poly(L-lactic add), polycaprolactone, poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(lactic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters) (e.g. PEO/PLA), polyalkylene oxalates, polyphosphazenes and biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen, hyaluronic acid copolymers are also contemplated.


The present invention also provides kits comprising a stent or stents according to the present invention. In addition to a stent or stents, a kit according to the present invention may include, for example, delivery catheter(s), balloon(s), and/or instructions for use. In kits according to the present invention, the stent(s) may be mounted in or on a balloon or catheter. Alternatively, the stent(s) may be separate from the balloon or catheter and may be mounted therein or thereon prior to use.


While the invention has been described in conjunction with specific embodiments and examples thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art upon reading the present disclosure. One or more features of one embodiment can be used in other embodiments. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

Claims
  • 1. A bifurcation stent, comprising: a tubular member having an inner diameter and an outer diameter defining a wall therebetween, the wall having a geometrical configuration defining a pattern; andan expandable branch structure formed in the wall of the tubular structure and interrupting the wall pattern, the expandable branch structure being connected to the tubular member at a plurality of locations, the expandable branch structure having a first ring connected to the tubular member, a second ring connected to the first ring and a third ring connected to the second ring,wherein the expandable branch structure includes a distal portion and a proximal portion, and at least one partial distal ring is connected to the first ring at the distal portion and at least one partial proximal ring is connected to the first ring at the proximal portion, and wherein the rings and the partial rings at the proximal and distal portions form a lattice portion,wherein the third ring substantially surrounds and defines a central branch opening, andwherein the expandable branch structure is movable from an unexpanded configuration to an expanded configuration, in the unexpanded configuration the expandable branch structure is disposed along the wall and in the expanded configuration the expandable branch structure extends outwardly from the tubular member.
  • 2. The stent according to claim 1, wherein the tubular member has a longitudinal axis and the expandable branch structure is disposed substantially perpendicular to the longitudinal axis in the expanded configuration.
  • 3. The stent according to claim 1, wherein the tubular member comprises a plurality of undulating rings disposed along the longitudinal axis and the undulating rings are connected by connectors.
  • 4. The stent according to claim 1, wherein the first, second and third rings have a common axis disposed substantially perpendicular to the longitudinal axis in the unexpanded configuration.
  • 5. The stent according to claim 1, wherein the branch structure includes a transition structure.
  • 6. The stent according to claim 5, wherein the transition structure comprises a discontinuous portion.
  • 7. The stent according to claim 6, wherein the first ring connects to the discontinuous portion, connects the first ring to a portion of the wall pattern outside the extendible branch structure.
  • 8. The stent according to claim 5, wherein the first, second and third rings are connected by connectors.
  • 9. The stent according to claim 8, wherein the connectors are generally undulating curvilinear members.
  • 10. The stent according to claim 8, wherein the connectors are generally straight members.
  • 11. The stent according to claim 3, wherein the first, second and third rings are generally continuous undulating curvilinear members and include undulation peaks.
  • 12. The stent according to claim 1, wherein the stent is comprised of biodegradable material.
  • 13. The stent according to claim 1, wherein the stent is comprised of a material and is coated with a biodegradable material.
  • 14. The stent according to claim 1, wherein the stent is one of comprised of or coated with a biodegradable material including a drug embedded in the material, whereby upon degradation of the biodegradable material, the drug is controllably released.
  • 15. The stent according to claim 12, wherein the biodegradable material is at least one of polyglycolic acid, polylactic acid, copolymers of polyglycolic acid and polylactic acid, polyorthoesters, polyaminoacids and polyanhydides.
  • 16. The stent according to claim 13, wherein the biodegradable material is at least one of polyglycolic acid, polylactic acid, copolymers of polyglycolic acid and polylactic acid, polyorthoesters, polyaminoacids and polyanhydides.
  • 17. The stent according to claim 14, wherein the drug can be embedded in the material in one amount on the expandable branch structure and in another amount on a remainder of the tubular member.
  • 18. The stent according to claim 1, wherein the first, second and third rings are concentric.
  • 19. The stent according to claim 1, wherein the first ring is connected to a tubular member by a connector having at least one cell.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation-in-part of U.S. patent application Ser. No. 10/802,036, filed Mar. 17, 2004 now U.S. Pat. No. 7,341,598, which is a continuation-in-part of U.S. patent application Ser. No. 10/705,247, filed Nov. 12, 2003 now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 10/644,550, filed Aug. 21, 2003 now U.S. Pat. No. 7,220,275, the entire contents of which are incorporated herein by reference.

US Referenced Citations (469)
Number Name Date Kind
1596754 Moschelle Aug 1926 A
3657744 Ersek Apr 1972 A
3872893 Roberts Mar 1975 A
4140126 Choudhury Feb 1979 A
4309994 Grunwald Jan 1982 A
4410476 Redding et al. Oct 1983 A
4413989 Schjeldahl Nov 1983 A
4421810 Rasmussen Dec 1983 A
4453545 Inoue Jun 1984 A
4503569 Dotter Mar 1985 A
4552554 Gould et al. Nov 1985 A
4681570 Dalton Jul 1987 A
4689174 Lupke Aug 1987 A
4731055 Melinyshyn et al. Mar 1988 A
4733665 Palmaz Mar 1988 A
4739762 Palmaz Apr 1988 A
4759748 Reed Jul 1988 A
4762128 Rosenbluth Aug 1988 A
4769005 Ginsburg et al. Sep 1988 A
4769029 Patel Sep 1988 A
4774949 Fogarty Oct 1988 A
4819664 Nazari Apr 1989 A
4872874 Taheri Oct 1989 A
4878495 Grayzel Nov 1989 A
4896670 Crittenden Jan 1990 A
4900314 Quackenbush Feb 1990 A
4905667 Foerster et al. Mar 1990 A
4906244 Pinchuk et al. Mar 1990 A
4909258 Kuntz et al. Mar 1990 A
4946464 Pevsner Aug 1990 A
4957501 Lahille et al. Sep 1990 A
4957508 Kaneko et al. Sep 1990 A
4964850 Bouton et al. Oct 1990 A
4983167 Sahota Jan 1991 A
4994071 MacGregor Feb 1991 A
5042976 Ishitsu et al. Aug 1991 A
5054501 Chuttani et al. Oct 1991 A
5059177 Towne et al. Oct 1991 A
5061240 Cherian Oct 1991 A
5064435 Porter Nov 1991 A
5085664 Bozzo Feb 1992 A
5102403 Alt Apr 1992 A
5102417 Palmaz Apr 1992 A
5104404 Wolff Apr 1992 A
5117831 Jang Jun 1992 A
5122125 Deuss Jun 1992 A
5135536 Hillstead Aug 1992 A
5147317 Shank et al. Sep 1992 A
5159920 Condon et al. Nov 1992 A
5176617 Fischell et al. Jan 1993 A
5192297 Hull Mar 1993 A
5195984 Schatz Mar 1993 A
5211683 Maginot May 1993 A
5217440 Frassica Jun 1993 A
5222971 Willard et al. Jun 1993 A
5226913 Pinchuk Jul 1993 A
5234457 Andersen Aug 1993 A
5236446 Dumon Aug 1993 A
5257974 Cox Nov 1993 A
5263932 Jang Nov 1993 A
5282472 Companion et al. Feb 1994 A
5304220 Maginot Apr 1994 A
5320605 Sahota Jun 1994 A
5324257 Osborne et al. Jun 1994 A
5337733 Bauerfeind et al. Aug 1994 A
5338300 Cox Aug 1994 A
5342295 Imran Aug 1994 A
5342297 Jang Aug 1994 A
5342387 Summers Aug 1994 A
5350395 Yock Sep 1994 A
5383892 Cardon Jan 1995 A
5387235 Chuter Feb 1995 A
5395332 Ressemann et al. Mar 1995 A
5395334 Keith et al. Mar 1995 A
5404887 Prather Apr 1995 A
5409458 Khairkhahan et al. Apr 1995 A
5413581 Goy May 1995 A
5413586 Dibie et al. May 1995 A
5417208 Winkler May 1995 A
5425765 Tiefenbrun et al. Jun 1995 A
5437638 Bowman Aug 1995 A
5443497 Venbrux Aug 1995 A
5445624 Jimenez Aug 1995 A
5449373 Pinchasik et al. Sep 1995 A
5449382 Dayton Sep 1995 A
5456694 Marin et al. Oct 1995 A
5456712 Maginot Oct 1995 A
5456714 Owen Oct 1995 A
5458605 Klemm Oct 1995 A
5462530 Jang Oct 1995 A
5476471 Shifrin et al. Dec 1995 A
5487730 Marcadis et al. Jan 1996 A
5489271 Anderson Feb 1996 A
5489295 Piplani et al. Feb 1996 A
5496292 Burnham Mar 1996 A
5505702 Arney Apr 1996 A
5507768 Lau Apr 1996 A
5507769 Marin et al. Apr 1996 A
5514154 Lau et al. May 1996 A
5514178 Torchio May 1996 A
5522801 Wang Jun 1996 A
5531788 Dibie et al. Jul 1996 A
5545132 Fagan et al. Aug 1996 A
5549553 Ressemann et al. Aug 1996 A
5549554 Miraki Aug 1996 A
5562620 Klein et al. Oct 1996 A
5562724 Vorwerk et al. Oct 1996 A
5562725 Schmitt et al. Oct 1996 A
5562726 Chuter Oct 1996 A
5569295 Lam Oct 1996 A
5571087 Ressemann et al. Nov 1996 A
5575771 Walinsky Nov 1996 A
5575817 Martin Nov 1996 A
5575818 Pinchuk Nov 1996 A
5591228 Edoga Jan 1997 A
5593442 Klein Jan 1997 A
5607444 Lam Mar 1997 A
5609605 Marshall et al. Mar 1997 A
5609625 Piplani et al. Mar 1997 A
5609627 Goicoechea et al. Mar 1997 A
5609629 Fearnot et al. Mar 1997 A
5613949 Miraki Mar 1997 A
5613980 Chauhan Mar 1997 A
5613981 Boyle et al. Mar 1997 A
5617878 Taheri Apr 1997 A
5626600 Horzewski et al. May 1997 A
5628788 Pinchuk May 1997 A
5632762 Myler May 1997 A
5632763 Glastra May 1997 A
5632772 Alcime et al. May 1997 A
5634902 Johnson et al. Jun 1997 A
5636641 Fariabi Jun 1997 A
5639278 Dereume et al. Jun 1997 A
5643340 Nunokawa Jul 1997 A
5653743 Martin Aug 1997 A
5662614 Edoga Sep 1997 A
5669924 Shaknovich Sep 1997 A
5669932 Fischell et al. Sep 1997 A
5676696 Morcade Oct 1997 A
5676697 McDonald Oct 1997 A
5679400 Tuch Oct 1997 A
5683450 Goicoechea et al. Nov 1997 A
5683451 Lenker et al. Nov 1997 A
5690642 Osborne et al. Nov 1997 A
5693084 Chuter Dec 1997 A
5693086 Goicoechea et al. Dec 1997 A
5693088 Lazarus Dec 1997 A
5697971 Fischell et al. Dec 1997 A
5707348 Krogh Jan 1998 A
5707354 Salmon Jan 1998 A
5709713 Evans et al. Jan 1998 A
5716365 Goicoechea et al. Feb 1998 A
5718683 Ressemann et al. Feb 1998 A
5718724 Goicoechea et al. Feb 1998 A
5720735 Dorros Feb 1998 A
5723004 Dereume et al. Mar 1998 A
5724977 Yock et al. Mar 1998 A
5728158 Lau et al. Mar 1998 A
5733303 Israel et al. Mar 1998 A
5735893 Lau et al. Apr 1998 A
5746766 Edoga May 1998 A
5749825 Fischell et al. May 1998 A
5749848 Jang et al. May 1998 A
5749890 Shaknovich May 1998 A
5755734 Richter et al. May 1998 A
5755735 Richter et al. May 1998 A
5755770 Ravenscroft May 1998 A
5755771 Penn et al. May 1998 A
5755773 Evans et al. May 1998 A
5755778 Kleshinski May 1998 A
5762631 Klein Jun 1998 A
5776101 Goy Jul 1998 A
5776161 Globerman Jul 1998 A
5776180 Goicoechea et al. Jul 1998 A
5782906 Marshall et al. Jul 1998 A
5800450 Lary et al. Sep 1998 A
5800508 Goicoechea et al. Sep 1998 A
5814061 Osborne et al. Sep 1998 A
5817126 Imran Oct 1998 A
5824008 Bolduc et al. Oct 1998 A
5824036 Lauterjung Oct 1998 A
5824040 Cox et al. Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824044 Quiachon et al. Oct 1998 A
5827320 Richter et al. Oct 1998 A
5833650 Imran Nov 1998 A
5836966 St. Germain Nov 1998 A
5837008 Berg et al. Nov 1998 A
5843031 Hermann et al. Dec 1998 A
5843160 Rhodes Dec 1998 A
5843164 Frantzen et al. Dec 1998 A
5846204 Solomon Dec 1998 A
5851210 Torossian Dec 1998 A
5851464 Davila et al. Dec 1998 A
5855600 Alt Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5865178 Yock Feb 1999 A
5868777 Lam Feb 1999 A
5871536 Lazarus Feb 1999 A
5871537 Holman et al. Feb 1999 A
5891133 Murphy-Chutorian Apr 1999 A
5893887 Jayaraman Apr 1999 A
5897588 Hull et al. Apr 1999 A
5906640 Penn et al. May 1999 A
5907893 Zadno-Azizi et al. Jun 1999 A
5913895 Burpee et al. Jun 1999 A
5913897 Corso, Jr. et al. Jun 1999 A
5921958 Ressemann et al. Jul 1999 A
5922020 Klein et al. Jul 1999 A
5925061 Ogi et al. Jul 1999 A
5928248 Acker Jul 1999 A
5938682 Hojeibane Aug 1999 A
5938696 Goicoechea et al. Aug 1999 A
5948016 Jang Sep 1999 A
5951599 McCrory Sep 1999 A
5961548 Shmulewitz Oct 1999 A
5967986 Cimochowski et al. Oct 1999 A
5972017 Berg et al. Oct 1999 A
5972018 Israel et al. Oct 1999 A
6007517 Anderson Dec 1999 A
6013054 Jiun Yan Jan 2000 A
6013091 Ley et al. Jan 2000 A
6017324 Tu et al. Jan 2000 A
6017363 Hojeibane Jan 2000 A
6024763 Lenker et al. Feb 2000 A
6030414 Taheri Feb 2000 A
6033434 Borghi Mar 2000 A
6033435 Penn et al. Mar 2000 A
6036682 Lange et al. Mar 2000 A
6039749 Marin et al. Mar 2000 A
6042597 Kveen et al. Mar 2000 A
6045557 White et al. Apr 2000 A
6048361 Von Oepen Apr 2000 A
6056775 Borghi et al. May 2000 A
6059823 Holman et al. May 2000 A
6059824 Taheri May 2000 A
6066168 Lau et al. May 2000 A
6068655 Seguin et al. May 2000 A
6071285 Lashinski et al. Jun 2000 A
6086611 Duffy et al. Jul 2000 A
6090127 Globerman Jul 2000 A
6090128 Douglas Jul 2000 A
6093203 Uflacker Jul 2000 A
6096073 Webster et al. Aug 2000 A
6099497 Adams et al. Aug 2000 A
6113579 Eidenschink et al. Sep 2000 A
6117117 Mauch Sep 2000 A
6117156 Richter et al. Sep 2000 A
6126685 Lenker et al. Oct 2000 A
6129738 Lashinski et al. Oct 2000 A
6129754 Kanesaka et al. Oct 2000 A
6142973 Carleton et al. Nov 2000 A
6143002 Vietmeier Nov 2000 A
6152945 Bachinski et al. Nov 2000 A
6159238 Killion et al. Dec 2000 A
6165195 Wilson et al. Dec 2000 A
6165197 Yock Dec 2000 A
6165214 Lazarus Dec 2000 A
6168621 Vrba Jan 2001 B1
6179867 Cox Jan 2001 B1
6183506 Penn et al. Feb 2001 B1
6183509 Dibie Feb 2001 B1
6187033 Schmitt et al. Feb 2001 B1
6190403 Fischell et al. Feb 2001 B1
6193746 Strecker Feb 2001 B1
6203568 Lombardi et al. Mar 2001 B1
6203569 Wijay Mar 2001 B1
6210380 Mauch Apr 2001 B1
6210429 Vardi et al. Apr 2001 B1
6210433 Larre Apr 2001 B1
6217527 Selmon et al. Apr 2001 B1
6217608 Penn et al. Apr 2001 B1
6221080 Power Apr 2001 B1
6221090 Wilson Apr 2001 B1
6221098 Wilson et al. Apr 2001 B1
6231563 White et al. May 2001 B1
6231598 Berry et al. May 2001 B1
6231600 Zhong May 2001 B1
6235051 Murphy May 2001 B1
6241762 Shanley Jun 2001 B1
6254593 Wilson Jul 2001 B1
6258073 Mauch Jul 2001 B1
6258099 Mareiro et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258116 Hojeibane Jul 2001 B1
6258121 Yang et al. Jul 2001 B1
6261273 Ruiz Jul 2001 B1
6261305 Marotta et al. Jul 2001 B1
6261316 Shaolian et al. Jul 2001 B1
6261319 Kveen et al. Jul 2001 B1
6264662 Lauterjung Jul 2001 B1
6264682 Wilson et al. Jul 2001 B1
6264686 Rieu et al. Jul 2001 B1
6273911 Cox et al. Aug 2001 B1
6273913 Wright et al. Aug 2001 B1
6287314 Lee et al. Sep 2001 B1
6290673 Shanley Sep 2001 B1
6293967 Shanley Sep 2001 B1
6293968 Taheri Sep 2001 B1
6299634 Bergeron Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6309412 Lau et al. Oct 2001 B1
6309414 Rolando et al. Oct 2001 B1
6312459 Huang et al. Nov 2001 B1
6325821 Gaschino et al. Dec 2001 B1
6325822 Chouinard Dec 2001 B1
6325826 Vardi et al. Dec 2001 B1
6334864 Amplatz et al. Jan 2002 B1
6334870 Her et al. Jan 2002 B1
6346089 Dibie Feb 2002 B1
6350278 Lenker et al. Feb 2002 B1
6355060 Lenker et al. Mar 2002 B1
6361544 Wilson et al. Mar 2002 B1
6361555 Wilson Mar 2002 B1
6383213 Wilson et al. May 2002 B2
6383215 Sass May 2002 B1
6387120 Wilson et al. May 2002 B2
6395018 Castaneda May 2002 B1
6398792 O'Connor Jun 2002 B1
6398804 Spielberg Jun 2002 B1
6428570 Globerman Aug 2002 B1
6432133 Lau et al. Aug 2002 B1
6436104 Hojeibane Aug 2002 B2
6436134 Richter et al. Aug 2002 B2
6478816 Kveen et al. Nov 2002 B1
6482211 Choi Nov 2002 B1
6485511 Lau et al. Nov 2002 B2
6494905 Zedler et al. Dec 2002 B1
6508836 Wilson et al. Jan 2003 B2
6511504 Lau et al. Jan 2003 B1
6511505 Cox et al. Jan 2003 B2
6517558 Gittings et al. Feb 2003 B2
6520988 Colombo et al. Feb 2003 B1
6527799 Shanley Mar 2003 B2
6540719 Bigus et al. Apr 2003 B2
6540779 Richter et al. Apr 2003 B2
6572647 Supper Jun 2003 B1
6579309 Loos et al. Jun 2003 B1
6579312 Wilson et al. Jun 2003 B2
6582394 Reiss et al. Jun 2003 B1
6582459 Lau et al. Jun 2003 B1
6596020 Vardi et al. Jul 2003 B2
6596022 Lau et al. Jul 2003 B2
6599316 Vardi et al. Jul 2003 B2
6645241 Strecker Nov 2003 B1
6645242 Quinn Nov 2003 B1
6689156 Davidson et al. Feb 2004 B1
6692483 Vardi et al. Feb 2004 B2
6695877 Brucker et al. Feb 2004 B2
6706062 Vardi et al. Mar 2004 B2
6749628 Callol et al. Jun 2004 B1
6776793 Brown et al. Aug 2004 B2
6811566 Penn et al. Nov 2004 B1
6835203 Vardi et al. Dec 2004 B1
6858038 Heuser Feb 2005 B2
6884258 Vardi et al. Apr 2005 B2
6896699 Wilson et al. May 2005 B2
6932837 Amplatz et al. Aug 2005 B2
6955687 Richter et al. Oct 2005 B2
6955688 Wilson et al. Oct 2005 B2
6962602 Vardi et al. Nov 2005 B2
7018400 Lashinski et al. Mar 2006 B2
7056323 Mareiro et al. Jun 2006 B2
7060091 Killion et al. Jun 2006 B2
20010003161 Vardi et al. Jun 2001 A1
20010004706 Hojeibane Jun 2001 A1
20010004707 Dereurne et al. Jun 2001 A1
20010012927 Mauch Aug 2001 A1
20010016766 Vardi et al. Aug 2001 A1
20010016767 Wilson et al. Aug 2001 A1
20010016768 Wilson et al. Aug 2001 A1
20010025195 Shaolian et al. Sep 2001 A1
20010027291 Shanley Oct 2001 A1
20010027338 Greenberg Oct 2001 A1
20010029396 Wilson et al. Oct 2001 A1
20010037116 Wilson et al. Nov 2001 A1
20010037138 Wilson et al. Nov 2001 A1
20010037146 Lau et al. Nov 2001 A1
20010037147 Lau et al. Nov 2001 A1
20010039395 Mareiro et al. Nov 2001 A1
20010039448 Dibie Nov 2001 A1
20010047201 Cox et al. Nov 2001 A1
20010049552 Richter et al. Dec 2001 A1
20010056297 Hojeibane Dec 2001 A1
20020013618 Marotta et al. Jan 2002 A1
20020013619 Shanley Jan 2002 A1
20020022874 Wilson Feb 2002 A1
20020026232 Marotta et al. Feb 2002 A1
20020032478 Boekstegers et al. Mar 2002 A1
20020035392 Wilson Mar 2002 A1
20020042650 Vardi et al. Apr 2002 A1
20020052648 McGuckin et al. May 2002 A1
20020058990 Jang May 2002 A1
20020072790 McGuckin et al. Jun 2002 A1
20020107564 Cox et al. Aug 2002 A1
20020111675 Wilson Aug 2002 A1
20020123790 White et al. Sep 2002 A1
20020123797 Majercak Sep 2002 A1
20020123798 Burgermeister Sep 2002 A1
20020151959 Von Oepen Oct 2002 A1
20020156516 Vardi et al. Oct 2002 A1
20020156517 Perouse Oct 2002 A1
20020165604 Shanley Nov 2002 A1
20020173835 Bourang et al. Nov 2002 A1
20020173840 Brucker et al. Nov 2002 A1
20020177892 Globerman Nov 2002 A1
20020183763 Callol et al. Dec 2002 A1
20020193872 Trout et al. Dec 2002 A1
20020193873 Brucker et al. Dec 2002 A1
20030004535 Musbach et al. Jan 2003 A1
20030009209 Hojeibane Jan 2003 A1
20030009214 Shanley Jan 2003 A1
20030014102 Hong et al. Jan 2003 A1
20030023301 Cox et al. Jan 2003 A1
20030028233 Vardi et al. Feb 2003 A1
20030050688 Fischell et al. Mar 2003 A1
20030055378 Wang et al. Mar 2003 A1
20030055483 Gumm Mar 2003 A1
20030074047 Richter Apr 2003 A1
20030093109 Mauch May 2003 A1
20030097169 Brucker May 2003 A1
20030114912 Sequin et al. Jun 2003 A1
20030114915 Mareiro et al. Jun 2003 A1
20030125791 Sequin et al. Jul 2003 A1
20030125799 Limon et al. Jul 2003 A1
20030125802 Callol et al. Jul 2003 A1
20030135259 Simso Jul 2003 A1
20030181923 Vardi Sep 2003 A1
20030195606 Davidson et al. Oct 2003 A1
20030195609 Berenstein et al. Oct 2003 A1
20040006381 Sequin et al. Jan 2004 A1
20040015227 Vardi et al. Jan 2004 A1
20040044396 Clerc et al. Mar 2004 A1
20040049259 Strecker Mar 2004 A1
20040059406 Cully et al. Mar 2004 A1
20040072849 Schreiber et al. Apr 2004 A1
20040088007 Eidenschink May 2004 A1
20040117003 Ouriel et al. Jun 2004 A1
20040133268 Davidson et al. Jul 2004 A1
20040138732 Suhr et al. Jul 2004 A1
20040138737 Davidson et al. Jul 2004 A1
20040148006 Davidson et al. Jul 2004 A1
20040172121 Eidenschink et al. Sep 2004 A1
20040186560 Alt Sep 2004 A1
20040225345 Fischell et al. Nov 2004 A1
20040267352 Davidson et al. Dec 2004 A1
20050004656 Das Jan 2005 A1
20050010278 Vardi et al. Jan 2005 A1
20050015108 Williams et al. Jan 2005 A1
20050015135 Shanley Jan 2005 A1
20050060027 Khenansho et al. Mar 2005 A1
20050096726 Sequin et al. May 2005 A1
20050102021 Osborne May 2005 A1
20050102023 Yadin et al. May 2005 A1
20050119731 Brucker et al. Jun 2005 A1
20050125076 Ginn Jun 2005 A1
20050131526 Wong Jun 2005 A1
20050149161 Eidenschink et al. Jul 2005 A1
20050154442 Eidenschink et al. Jul 2005 A1
20050154444 Quadri Jul 2005 A1
20050183259 Eidenschink et al. Aug 2005 A1
20050209673 Shaked Sep 2005 A1
20050228483 Kaplan et al. Oct 2005 A1
20060036315 Yadin et al. Feb 2006 A1
20060041303 Israel Feb 2006 A1
20060079956 Eigler et al. Apr 2006 A1
20060173528 Feld et al. Aug 2006 A1
20070073376 Krolik et al. Mar 2007 A1
20070135904 Eidenschink Jun 2007 A1
Foreign Referenced Citations (133)
Number Date Country
2220864 Jul 1999 CA
2318314 Jul 1999 CA
9014845.2 Feb 1991 DE
29701758 May 1997 DE
0479730 Oct 1991 EP
551179 Jul 1993 EP
684022 Nov 1995 EP
0751752 Jan 1997 EP
804907 May 1997 EP
0783873 Jul 1997 EP
0479557 Jul 1998 EP
876805 Nov 1998 EP
0880949 Dec 1998 EP
884028 Dec 1998 EP
891751 Jan 1999 EP
0895759 Feb 1999 EP
897698 Feb 1999 EP
897700 Feb 1999 EP
904745 Mar 1999 EP
0937442 Aug 1999 EP
0347023 Dec 1999 EP
1031328 Aug 2000 EP
1031329 Aug 2000 EP
1031330 Aug 2000 EP
0883384 Dec 2000 EP
0862392 Aug 2001 EP
1157674 Nov 2001 EP
0808140 Dec 2001 EP
1190685 Mar 2002 EP
646365 Jan 2004 EP
1070513 Jun 2006 EP
2678508 Jan 1993 FR
2740346 Oct 1995 FR
2756173 Nov 1996 FR
2337002 May 1998 GB
WO 8806026 Aug 1988 WO
WO 9013332 Nov 1990 WO
WO 9112779 Sep 1991 WO
WO 9219308 Nov 1992 WO
WO 9508965 Apr 1995 WO
WO 9521592 Aug 1995 WO
WO 9629955 Oct 1996 WO
WO 9634580 Nov 1996 WO
WO 9641592 Dec 1996 WO
9707752 Mar 1997 WO
WO 9709946 Mar 1997 WO
9715346 May 1997 WO
WO 9716217 May 1997 WO
WO 9726936 Jul 1997 WO
WO 9732544 Sep 1997 WO
WO 9733532 Sep 1997 WO
WO 9741803 Nov 1997 WO
9746174 Dec 1997 WO
WO 9745073 Dec 1997 WO
WO 9817204 Apr 1998 WO
WO 9819628 May 1998 WO
WO 9835634 Aug 1998 WO
WO 9836709 Aug 1998 WO
WO 9837833 Sep 1998 WO
9847447 Oct 1998 WO
WO 9844871 Oct 1998 WO
9848879 Nov 1998 WO
WO 9848733 Nov 1998 WO
WO 9852497 Nov 1998 WO
9903426 Jan 1999 WO
9904726 Feb 1999 WO
9915109 Apr 1999 WO
WO 9915103 Apr 1999 WO
WO 9917680 Apr 1999 WO
9924104 May 1999 WO
9936015 Jul 1999 WO
WO 9934749 Jul 1999 WO
WO 9936002 Jul 1999 WO
WO 9939661 Aug 1999 WO
9944539 Sep 1999 WO
9956661 Nov 1999 WO
WO 9958059 Nov 1999 WO
WO 9965419 Dec 1999 WO
WO 0000104 Jan 2000 WO
0007523 Feb 2000 WO
0010489 Mar 2000 WO
0016719 Mar 2000 WO
WO 0012166 Mar 2000 WO
WO 0013613 Mar 2000 WO
0027307 May 2000 WO
0027463 May 2000 WO
0028922 May 2000 WO
0044307 Aug 2000 WO
0044309 Aug 2000 WO
0047134 Aug 2000 WO
0048531 Aug 2000 WO
0049951 Aug 2000 WO
0051523 Sep 2000 WO
WO 0053122 Sep 2000 WO
0057813 Oct 2000 WO
0067673 Nov 2000 WO
0071054 Nov 2000 WO
0071055 Nov 2000 WO
WO 0074595 Dec 2000 WO
WO 0121095 Mar 2001 WO
WO 0121109 Mar 2001 WO
WO 0121244 Mar 2001 WO
0135715 May 2001 WO
0135863 May 2001 WO
0139697 Jun 2001 WO
0139699 Jun 2001 WO
0141677 Jun 2001 WO
0143665 Jun 2001 WO
0143809 Jun 2001 WO
0145594 Jun 2001 WO
0145785 Jun 2001 WO
0149342 Jul 2001 WO
0154621 Aug 2001 WO
0154622 Aug 2001 WO
0158385 Aug 2001 WO
0160284 Aug 2001 WO
0170294 Sep 2001 WO
WO 0170299 Sep 2001 WO
0174273 Oct 2001 WO
0189409 Nov 2001 WO
0200138 Jan 2002 WO
02053066 Jul 2002 WO
WO 02068012 Sep 2002 WO
WO 02076333 Oct 2002 WO
WO 02094336 Nov 2002 WO
03007842 Jan 2003 WO
WO 03055414 Jul 2003 WO
03063924 Aug 2003 WO
2004026174 Apr 2004 WO
WO 2004026180 Apr 2004 WO
2005009295 Feb 2005 WO
WO 2005014077 Feb 2005 WO
2006028925 Mar 2006 WO
Related Publications (1)
Number Date Country
20050102023 A1 May 2005 US
Continuation in Parts (3)
Number Date Country
Parent 10802036 Mar 2004 US
Child 11010730 US
Parent 10705247 Nov 2003 US
Child 10802036 US
Parent 10644550 Aug 2003 US
Child 10705247 US